Clinical Trial Detail

NCT ID NCT02134912
Title S1300: Pemetrexed Disodium With or Without Crizotinib in Treating Patients With Stage IV Non-Small Cell Lung Cancer That Has Progressed After Crizotinib
Recruitment Terminated
Gender both
Phase Phase II
Variant Requirements Yes
Sponsors Southwest Oncology Group
Indications

lung non-small cell carcinoma

Therapies

Crizotinib + Pemetrexed Disodium

Pemetrexed Disodium

Age Groups: adult

Additional content available in CKB BOOST